Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
18. Januar 2024 07:45 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals to Present at the Biotech Showcase 2024
02. Januar 2024 17:06 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
19. Dezember 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine
13. Dezember 2023 09:00 ET
|
Processa Pharmaceuticals, Inc.
FDA provides guidance on Phase 2 design and Processa to continue with pre-study activities for Phase 2 trial HANOVER, MD, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq:...
Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference
30. November 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
29. November 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company now focused on developing the next...
Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
13. November 2023 13:40 ET
|
Processa Pharmaceuticals, Inc.
Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November...
Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas
09. November 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
01. November 2023 08:15 ET
|
Processa Pharmaceuticals, Inc.
Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) --...
Processa Pharmaceuticals to Present at the ThinkEquity Conference
13. Oktober 2023 13:08 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...